Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

This study (BLAZE) is testing two cancer immunotherapy drugs — belzutifan and pembrolizumab — alone or in combination, given before surgery (neoadjuvant therapy) in people with clear cell kidney cancer (ccRCC) that is at intermediate-high risk, high risk, or has spread to limited nearby sites. **You may be eligible if...** - You are 18 or older with clear cell renal cell carcinoma (kidney cancer) confirmed by biopsy - Your cancer is at intermediate-high risk, high risk, or has isolated metastases that can be removed with the kidney - You have been evaluated by urology and are a candidate for kidney removal surgery - Your overall health is good (ECOG 0–1) - No distant metastases are seen on imaging done within the past 42 days **You may NOT be eligible if...** - You have had recent brain imaging showing spread to the brain - You have another active cancer that could interfere with the study - You do not meet the pathological staging or grade criteria Talk to your doctor to see if this trial is right for you.